We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
After Gilead Sciences’ remdesivir was approved for emergency use on COVID-19 patients, a number of other trials have gotten underway to test the antiviral’s benefits in combination with other drugs. Read More
The FDA yesterday updated its March guidance on managing clinical trials during COVID-19 by saying that sites can conduct patient visits via video conference with some advance planning. Read More
Sponsors of drugs to treat or prevent COVID-19 should focus on populations that are the hardest hit and least represented in clinical trials, including minorities and the elderly, according to a new FDA guidance released yesterday. Read More
The study also saw a greater portion of patients taking hydroxychloroquine with azithromycin experiencing cardiac arrest than those taking either medication alone. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) is giving Novavax an additional $384 million for development of its COVID-19 vaccine. Read More
The National Institutes of Health is sponsoring a clinical trial of Gilead Sciences’ antiviral remdesivir combined with Eli Lilly’s anti-inflammatory Olumiant (baricitinib) for treatment of COVID-19 infections. Read More